What development phase is 6-Furfuryladenine in?

6-Furfuryladenine is FDA-approved (marketed).

What is the generic name of 6-Furfuryladenine?

kinetin is the generic (nonproprietary) name of 6-Furfuryladenine.

Last reviewed 2026-04-20 · How we verify

6-Furfuryladenine (kinetin)

FDA-approved active Quality 10/100

At a glance

Generic name	kinetin
Target	Endochitinase
Therapeutic area	Oncology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Safety and Tolerability of Kinetin, in Patients With Familial Dysautonomia (PHASE1)
Efficacy and Safety of Kinetin 0.1% for Treatment of Skin Photoaging (PHASE4)
Efficacy and Safety Study of Kinerase® for Treatment of Cutaneous Facial Photodamage (PHASE4)
An Evaluation of Kinerase Pro+Therapy Regimen Vs. Kinerase Vs. Control for the Treatment of Skin Aging (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

6-Furfuryladenine CI brief — competitive landscape report
6-Furfuryladenine updates RSS · CI watch RSS
portfolio CI